100-fold improvement in sight seen after gene therapy trial
Vision improved 100 times on average in 15 people with Leber congenital amaurosis after gene therapy targeted mutations in the GUCY2D gene. The Phase I/II trial, co-led by researchers from the Perelman School of Medicine at the University of Pennsylvania and published in The Lancet, included three pediatric patients. Some patients receiving the highest dose experienced a 10,000-fold improvement. One patient reported navigating outdoors at midnight with only the light of a bonfire.
The therapy improved severe vision loss caused by LCA1, a rare inherited condition affecting less than 100,000 people worldwide.
Source: 100-fold improvement in sight seen after gene therapy trial (medicalxpress.com).
Written by the HappyGood desk from the primary source linked above and checked against it. Every story links its source. Corrections: hello@happygood.news.
More from the archive
- Blind Herefordshire writer gains international acclaim for debut short film Blind Faith October 18, 2026
- At 91, Barrie man stays active every day at East Bayfield Community Centre October 18, 2026
- Wrexham care home residents take nostalgic train ride through Dee Valley October 17, 2026
- Roslin pupils sow wildflower meadow by hand at Roslin Glen October 16, 2026
- Oyster sanctuary network in North Carolina's Pamlico Sound reaches 500-acre goal October 16, 2026